Journal: Nature communications
This study evaluated the real-world performance of the Galleri® multi-cancer early detection (MCED) blood test in over 111,000 individuals.
The test detects cancer signals by analyzing methylation patterns of cell-free DNA and predicts the cancer signal origin (CSO).
The cancer signal detection rate was 0.91%, consistent with prior clinical data.
Among 459 patients with follow-up, 258 were diagnosed with invasive cancers across 32 types.
The test accurately predicted the CSO in 87% of cases, facilitating targeted diagnostic workup with a median time of 39.5 days from test result to diagnosis.
These findings support the MCED test’s utility for early, multi-cancer detection and efficient clinical evaluation.